Core Insights - The company reported a revenue of 571 million yuan for the first three quarters of 2025, representing a year-on-year decline of 35.33% [1] - The net profit attributable to the company was -14.79 million yuan, a year-on-year decrease of 111.14% [1] Business Performance - The company indicated that the order scale and business quality improved simultaneously, with a steady increase in order reserves [1] - New signed orders increased by 29.37% year-on-year, highlighting growth in the company's core business [1] - The number of new drug clinical trial applications (IND) and new drug marketing applications (NDA) signed increased by 30.71% year-on-year, with contract amounts rising by 23.06% [1] Future Outlook - As of the end of the reporting period, the amount of orders on hand grew by 19.43% compared to the end of 2024, providing a solid foundation for future operations [1]